HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ATP13A2
ATPase cation transporting 13A2
Chromosome 1 Β· 1p36.13
NCBI Gene: 23400Ensembl: ENSG00000159363.19HGNC: HGNC:30213UniProt: Q8N4D4
125PubMed Papers
22Diseases
0Drugs
91Pathogenic Variants
FUNCTIONAL ROLE
Transporter
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
spermine transmembrane transportautophagosome organizationregulation of lysosomal protein catabolic processtransport vesicleKufor-Rakeb syndromeautosomal recessive spastic paraplegia type 78Spastic paraplegiagenetic disorder
✦AI Summary

ATP13A2 is a lysosomal polyamine exporter functioning as a critical regulator of cellular homeostasis and neuronal integrity 1. The protein exhibits highest affinity for spermine among polyamines and facilitates their cytosolic export while promoting cellular polyamine uptake via endocytosis, protecting against polyamine-induced toxicity 1. Beyond polyamine transport, ATP13A2 maintains intracellular cation homeostasis, regulates zinc and manganese handling, and confers protection against heavy metal and mitochondrial stress. The protein coordinates lysosomal and mitochondrial maintenance through autophagy regulation, recruiting HDAC6 to deacetylate CTTN and promoting autophagosome-lysosome fusion 1. Loss of ATP13A2 function causes lysosomal rupture, cathepsin B activation, and compromised autophagy, mechanisms underlying neurodegeneration 1. ATP13A2 mutations cause Kufor-Rakeb syndrome, characterized by juvenile-onset parkinsonism with dementia, pyramidal degeneration, and supranuclear palsy 2. The gene is also implicated in atypical parkinsonism and neurodegeneration with brain iron accumulation (NBIA) 34. Disease-associated ATP13A2 mutations show functional impairment correlating with disease severity. Recent research highlights disturbed polyamine homeostasis as a key pathogenic mechanism in Parkinson's disease associated with ATP13A2 dysfunction 5.

Sources cited
1
ATP13A2 functions as a lysosomal polyamine exporter with highest affinity for spermine, promotes cellular polyamine uptake, protects against polyamine toxicity, and loss causes lysosomal dysfunction and cathepsin B activation
PMID: 31996848
2
ATP13A2 mutations cause Kufor-Rakeb syndrome with juvenile-onset parkinsonism, dementia, pyramidal degeneration, and supranuclear palsy
PMID: 25197640
3
ATP13A2 mutations cause atypical or complex parkinsonism and are implicated in monogenic Parkinson's disease
PMID: 35328025
4
ATP13A2 mutations cause Kufor-Rakeb disease, an ultrarare neurodegeneration with brain iron accumulation disorder
PMID: 29325618
5
ATP13A2 (PARK9) dysfunction demonstrates a driving role of disturbed polyamine homeostasis in Parkinson's disease pathogenesis
PMID: 37018845
Disease Associationsβ“˜22
Kufor-Rakeb syndromeOpen Targets
0.84Strong
autosomal recessive spastic paraplegia type 78Open Targets
0.81Strong
Spastic paraplegiaOpen Targets
0.57Moderate
genetic disorderOpen Targets
0.53Moderate
Parkinson diseaseOpen Targets
0.52Moderate
neurodegeneration with brain iron accumulationOpen Targets
0.52Moderate
Abnormality of the skeletal systemOpen Targets
0.51Moderate
DystoniaOpen Targets
0.51Moderate
complex hereditary spastic paraplegiaOpen Targets
0.50Moderate
Hereditary late-onset Parkinson diseaseOpen Targets
0.50Moderate
Varicose veinsOpen Targets
0.48Moderate
parkinsonism due to ATP13A2 deficiencyOpen Targets
0.37Weak
heart diseaseOpen Targets
0.33Weak
obesityOpen Targets
0.31Weak
spontaneous abortionOpen Targets
0.31Weak
vein disorderOpen Targets
0.30Weak
ovarian cancerOpen Targets
0.30Weak
lymphatic system diseaseOpen Targets
0.29Weak
radiation injuryOpen Targets
0.25Weak
smoking behaviorOpen Targets
0.15Weak
Kufor-Rakeb syndromeUniProt
Spastic paraplegia 78, autosomal recessiveUniProt
Pathogenic Variants91
NM_022089.4(ATP13A2):c.3057del (p.Tyr1020fs)Pathogenic
Kufor-Rakeb syndrome|not provided|Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome|Neurodegeneration with brain iron accumulation|Autosomal recessive spastic paraplegia type 78|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 1020
NM_022089.4(ATP13A2):c.1903C>T (p.Gln635Ter)Pathogenic
Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome|Autosomal recessive spastic paraplegia type 78|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 635
NM_022089.4(ATP13A2):c.1510G>C (p.Gly504Arg)Pathogenic
Kufor-Rakeb syndrome|Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome|See cases|Neurodegeneration with brain iron accumulation|Autosomal recessive spastic paraplegia type 78
β˜…β˜…β˜†β˜†2025β†’ Residue 504
NM_022089.4(ATP13A2):c.477+2T>GPathogenic
not provided|Kufor-Rakeb syndrome;Autosomal recessive spastic paraplegia type 78|Neurodegeneration with brain iron accumulation|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025
NM_022089.4(ATP13A2):c.2455C>T (p.Arg819Ter)Pathogenic
not provided|Kufor-Rakeb syndrome;Autosomal recessive spastic paraplegia type 78
β˜…β˜…β˜†β˜†2025β†’ Residue 819
NM_022089.4(ATP13A2):c.1436_1439del (p.Val479fs)Likely pathogenic
Autosomal recessive spastic paraplegia type 78|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 479
NM_022089.4(ATP13A2):c.2097del (p.Ser700fs)Pathogenic
Autosomal recessive spastic paraplegia type 78|Neurodegeneration with brain iron accumulation
β˜…β˜…β˜†β˜†2024β†’ Residue 700
NM_022089.4(ATP13A2):c.774G>A (p.Trp258Ter)Pathogenic
Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome|Neurodegeneration with brain iron accumulation|Kufor-Rakeb syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 258
NM_022089.4(ATP13A2):c.1306+5G>APathogenic
Kufor-Rakeb syndrome|Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome|not provided
β˜…β˜…β˜†β˜†2024
NM_022089.4(ATP13A2):c.2529+1G>APathogenic
Kufor-Rakeb syndrome|Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome
β˜…β˜…β˜†β˜†2024
NM_022089.4(ATP13A2):c.1459C>T (p.Arg487Ter)Pathogenic
Inborn genetic diseases|Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome
β˜…β˜…β˜†β˜†2023β†’ Residue 487
NM_022089.4(ATP13A2):c.1033_1034del (p.Leu345fs)Pathogenic
Kufor-Rakeb syndrome;Autosomal recessive spastic paraplegia type 78|ATP13A2-related disorder
β˜…β˜…β˜†β˜†2023β†’ Residue 345
NM_022089.4(ATP13A2):c.2116C>T (p.Gln706Ter)Pathogenic
not provided|Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome
β˜…β˜…β˜†β˜†2022β†’ Residue 706
NM_022089.4(ATP13A2):c.604del (p.His202fs)Pathogenic
Inborn genetic diseases|Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome
β˜…β˜…β˜†β˜†2022β†’ Residue 202
NM_022089.4(ATP13A2):c.1657C>T (p.Arg553Ter)Pathogenic
Autosomal recessive spastic paraplegia type 78|Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome
β˜…β˜…β˜†β˜†2021β†’ Residue 553
NM_022089.4(ATP13A2):c.212G>A (p.Trp71Ter)Pathogenic
not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2018β†’ Residue 71
NM_022089.4(ATP13A2):c.2413-1G>CLikely pathogenic
Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome
β˜…β˜†β˜†β˜†2026
NM_022089.4(ATP13A2):c.3152_3156dup (p.Leu1053fs)Pathogenic
Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 1053
NM_022089.4(ATP13A2):c.2436C>G (p.Tyr812Ter)Likely pathogenic
Autosomal recessive spastic paraplegia type 78
β˜…β˜†β˜†β˜†2025β†’ Residue 812
NM_022089.4(ATP13A2):c.1354-9_1358delLikely pathogenic
Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome
β˜…β˜†β˜†β˜†2025
View on ClinVar β†—
Related Genes
PINK1Protein interaction100%MAPTProtein interaction93%PRKNProtein interaction92%GIGYF2Protein interaction89%GBA1Protein interaction89%PARK7Protein interaction89%
Tissue Expression6 tissues
Brain
100%
Lung
50%
Bone Marrow
46%
Ovary
28%
Liver
19%
Heart
15%
Gene Interaction Network
Click a node to explore
ATP13A2PINK1MAPTPRKNGIGYF2GBA1PARK7
PROTEIN STRUCTURE
Preparing viewer…
PDB7N72 Β· 2.50 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.71LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.59 [0.50–0.71]
RankingsWhere ATP13A2 stands among ~20K protein-coding genes
  • #3,754of 20,598
    Most Researched125 Β· top quartile
  • #838of 5,498
    Most Pathogenic Variants91 Β· top quartile
  • #5,474of 17,882
    Most Constrained (LOEUF)0.71
Genes detectedATP13A2
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing.
PMID: 35328025
Genes (Basel) Β· 2022
1.00
2
Neurodegeneration with brain iron accumulation.
PMID: 29325618
Handb Clin Neurol Β· 2018
0.90
3
Polyamines in Parkinson's Disease: Balancing Between Neurotoxicity and Neuroprotection.
PMID: 37018845
Annu Rev Biochem Β· 2023
0.80
4
Modeling Parkinson's Disease in C. elegans.
PMID: 29480229
J Parkinsons Dis Β· 2018
0.70
5
ATP13A2 deficiency disrupts lysosomal polyamine export.
PMID: 31996848
Nature Β· 2020
0.60